Bristol-Myers Squibb Company Insider Trading

BMY

Last 12 months

Insiders sold $2.29M and bought nothing on the open market.

81% of the selling was scheduled in advance under 10b5-1 plans. EVP,Chief Med Offr,Head of Dev Cristian Massacesi sold 403K on Sep 9, 25% of their stake, outside a plan. The last open-market buy by an executive or director was in Apr 2025.

Net open-market

−$2.29M

0 buys · 3 sales

Under a 10b5-1 plan

81%

of the value sold

Insiders who bought / sold

0 / 3

executives and directors

Last open-market buy

Apr 2025

Apr 25, 2025

Get an email when BMY's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 9	Cristian Massacesi EVP,Chief Med Offr,Head of Dev	SoldNo plan	6,249	$64.57	403K	25%	Form 4
Aug 25	Phil M Holzer SVP and Controller	SoldNo plan	500	$67.50	34K	2.9%	Form 4
Apr 1	David V Elkins EVP, Chief Financial Officer	Sold10b5-1 plan 2 parts	30,000	$61.67 average	$1.85M	16%	Form 4
Sep 2, 2025	David V Elkins EVP, Chief Financial Officer	Sold10b5-1 plan	56,000	$47.33	$2.65M	25%	Form 4
Aug 2, 2025	Bartie Wendy Short EVP, Corporate Affairs	SoldNo plan	378	$44.23	17K	6.9%	Form 4
May 9, 2025	Benjamin Hickey President, RayzeBio Org.	SoldNo plan	97	$38.01	4K	1.1%	Form 4
Apr 25, 2025	Samit Hirawat EVP,Chief Med.Offr.,Drug Dev.	Bought	4,250	$47.58	202K	5.4%	Form 4
Feb 20, 2025	Christopher S. Boerner Chief Executive Officer	Bought	2,000	$55.05	110K	1.9%	Form 4
Feb 14, 2025	Samit Hirawat EVP,Chief Med.Offr.,Drug Dev.	Bought	1,823	$54.84	100K	2.9%	Form 4

Sep 9No plan
Cristian Massacesi
EVP,Chief Med Offr,Head of Dev · sold 6,249 at $64.57
403K
25% of stake
Aug 25No plan
Phil M Holzer
SVP and Controller · sold 500 at $67.50
34K
2.9% of stake
Apr 110b5-1 plan
David V Elkins
EVP, Chief Financial Officer · sold 30,000 at avg $61.67
$1.85M
16% of stake
Sep 2, 202510b5-1 plan
David V Elkins
EVP, Chief Financial Officer · sold 56,000 at $47.33
$2.65M
25% of stake
Aug 2, 2025No plan
Bartie Wendy Short
EVP, Corporate Affairs · sold 378 at $44.23
17K
6.9% of stake
May 9, 2025No plan
Benjamin Hickey
President, RayzeBio Org. · sold 97 at $38.01
4K
1.1% of stake
Apr 25, 2025
Samit Hirawat
EVP,Chief Med.Offr.,Drug Dev. · bought 4,250 at $47.58
202K
5.4% of stake
Feb 20, 2025
Christopher S. Boerner
Chief Executive Officer · bought 2,000 at $55.05
110K
1.9% of stake
Feb 14, 2025
Samit Hirawat
EVP,Chief Med.Offr.,Drug Dev. · bought 1,823 at $54.84
100K
2.9% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BMY, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with BMY

CompareIntrinsic value

ABTAbbott Laboratories

$115.55+5.62%25

PFEPfizer Inc.

$30.79+2.63%30

ABBVAbbVie Inc.

$294.83+3.09%49

MRKMerck & Co., Inc.

$150.36+3.93%41

UPCUniverse Pharmaceuticals Inc.

$1.47-1.34%39

TEVATeva Pharmaceutical Industries Ltd

$42.13+0.52%46

REGNRegeneron Pharmaceuticals, Inc.

$930.67-4.39%54

VTRSViatris Inc.

$19.22+1.59%24

Held by ETFs

BMY is in 428 US ETFs. The largest of them, with BMY's weight in each:

Spot a number that looks wrong? Check it in BMY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BMY

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.